Medmain Inc. (https://en.medmain.com), a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has been selected for the “U.S. Market Gateway Accelerator for BioSciences and MedTech”, an acceleration program sponsored by WorldUpstart, LLC. We will take advantage of this opportunity to move forward with our business development in the U.S.
The “U.S. Market Gateway Accelerator for BioSciences and MedTech”, sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market. The program receives applications from startups from all over the world, which must go through a rigorous evaluation process before being selected.
Through this program, the company will receive advice on business development in the U.S., ranging from FDA filings, marketing strategies for the U.S. healthcare market, intellectual property strategies, financing and business alliance strategies, and promotional support, among others.
We will also introduce PidPort, our AI-powered cloud system designed to support digital pathology, at the upcoming “Philadelphia Alliance for Capital and Technology Conference”, the largest annual startup conference in Philadelphia, which will be held in November.